EGFR and non-small cell lung carcinoma: A Phase Ib/II study (NCT03381274) evaluating the combination of oleclumab and the EGFR-TKI osimertinib in patients with advanced NSCLC harboring EGFR mutations was reported at the 2021 AACR meeting [325] and has been recently published [326].